In its announcement, OpenAI called GPT-Rosalind a "frontier reasoning model built to support research across biology, drug ...
When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has ...
For too long, MASLD care has relied on a narrow playbook: lifestyle advice, routine monitoring, and waiting for signs of ...
The ABPI, in the 3 rd March blog by Pinchas Kahtan, highlighted “early signs of a modest recovery in clinical trial ...
The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in ...
The British Business Bank (BB) has agreed to make a £100 million investment in a new healthcare fund launched by London-based ...
In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by ...
These documents are written in dense, lawyer-like language that requires individual interpretation from each function; ...
The revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple ...
In our final video from the LSX World Congress in Lisbon, Portugal, web editor Nicole Raleigh spoke with Paulo Neves, CMO of ...
Medicines are uniquely vulnerable to disruptions caused by conflict, as unlike many other goods, they are tightly regulated ...
With one approved drug (Johnson & Johnson’s Spavaro) already doing $468 million per quarter in sales, and with companies like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results